Strasbourg biotech appoints ceo

Mark Bloomfield aims to accelerate sales growth at Polyplus-transfection

Polyplus-transfection, a Strasbourg-based biotechnology firm developing solutions for scientists working in molecular and cell biology, has appointed Mark Bloomfield as chief executive.

Bloomfield replaces Frédéric Perraud who continues with Polyplus as chief operating officer and deputy ceo.

Polyplus is planning to accelerate revenue growth by launching reagents and solutions for cell transfection applications, by the commercialisation of ZNA technology through licensing agreements with Sigma-Aldrich and Metabion, as well as geographical sales channel expansion with partners in the US and major European and Asian markets.



Bloomfield has a background in chemistry and joins Polyplus-transfection after more than 15 years in sales and management positions with global companies in the biotechnology tools and analytical instruments markets.

‘I am very much looking forward to using my business experience with the company’s team of scientists, marketers and sales professionals to continue and accelerate its growth,’ said Bloomfield.

You may also like

Pharmaceutical

Polyplus introduces off-the-shelf plasmids for AAV2 production; plans to expand plasmid portfolio to support full range of AAV serotypes in 2024

Polyplus (part of Sartorius), a leading upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial grade, has launched pPLUS® AAV-RC2, a RepCap plasmid for adeno-associated virus vector 2 (AAV2) production
Research & Development

Polyplus-transfection raises €2.5m in funding

Will enable the firm to expand its therapeutic research activities
Regulatory

FDA approves Lilly's oral GLP-1 pill Foundayo for obesity with no food or water restrictions

Eli Lilly has received FDA approval for Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist for adults with obesity or overweight that requires no fasting or water restrictions, with clinical trial participants on the highest dose losing an average of 27 pounds
Pharmaceutical

Tekpak Automation to showcase pharma pick-and-place robotic cell at interpack 2026

Tekpak Automation will demonstrate the benefits of robotics for pharmaceutical applications at interpack 2026, with a LIVE working demonstration of a 3-axis pick-and-place cell handling medipens on Stand A15/Hall 16
Regulatory

FDA warns of drug-induced liver injury risk with Amgen's Tavneos after deaths

The US Food and Drug Administration has issued a safety warning linking Amgen's vasculitis drug Tavneos to 76 cases of drug-induced liver injury globally, including eight deaths and seven cases of vanishing bile duct syndrome, recommending comprehensive liver monitoring during the first five months of treatment
Manufacturing

Bio-Sourcing and Tiny Cargo collaborate to develop oral monoclonal antibody therapies

Bio-Sourcing and Tiny Cargo Company have announced a strategic alliance to co-develop oral monoclonal antibody therapies using goat milk extracellular vesicles
Regulatory

NICE approves KEYTRUDA as first perioperative immunotherapy for locally advanced head and neck cancer

MSD's KEYTRUDA (pembrolizumab) has received NICE approval as a neoadjuvant and adjuvant therapy for resectable LA HNSCC—the first immunotherapy recommended in this perioperative setting and the first treatment advance in more than two decades
Subscribe now